EditorialEditorial
Methotrexate in Giant Cell Arteritis Deserves a Second Chance — A High-dose Methotrexate Trial Is Needed
ELISABETH BROUWER, KORNELIS S.M. VAN DER GEEST and MARIA SANDOVICI
The Journal of Rheumatology May 2019, 46 (5) 453-454; DOI: https://doi.org/10.3899/jrheum.181306
ELISABETH BROUWER
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen (UMCG), University of Groningen, Groningen,
the Netherlands.
MD, PhDRoles: Associate Professor
KORNELIS S.M. VAN DER GEEST
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen (UMCG), University of Groningen, Groningen,
the Netherlands.
MD, PhDMARIA SANDOVICI
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen (UMCG), University of Groningen, Groningen,
the Netherlands.
MD, PhDREFERENCES
- 1.↵
- 2.↵
- 3.↵
- Koster MJ,
- Yeruva K,
- Crowson CS,
- Muratore F,
- Labarca C,
- Warrington KJ
- 4.↵
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- Yates M,
- Loke YK,
- Watts RA,
- MacGregor AJ
- 9.↵
- van der Veen MJ,
- Dinant HJ,
- van Booma-Frankfort C,
- van Albada-Kuipers GA,
- Bijlsma JW
- 10.↵
- Leon L,
- Rodriguez-Rodriguez L,
- Morado I,
- Rosales Z,
- Vadillo C,
- Freites D,
- et al.
In this issue
The Journal of Rheumatology
Vol. 46, Issue 5
1 May 2019
Methotrexate in Giant Cell Arteritis Deserves a Second Chance — A High-dose Methotrexate Trial Is Needed
ELISABETH BROUWER, KORNELIS S.M. VAN DER GEEST, MARIA SANDOVICI
The Journal of Rheumatology May 2019, 46 (5) 453-454; DOI: 10.3899/jrheum.181306